search
Back to results

Cystatin SN Binds to Phytic Acid and Predicts Non-heme Iron Bioavailability

Primary Purpose

Iron-deficiency, Iron Deficiency Anemia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
phytic acid
Sponsored by
Kansas State University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Iron-deficiency focused on measuring Phytic acid, Cystatin, Salivary proline-rich protein, antinutrient

Eligibility Criteria

18 Years - 35 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Female, 18-35 years' old
  • Non-obese BMI (18-29.9)
  • Signed informed consent

Exclusion Criteria:

  • Oral disease
  • Gastrointestinal disease
  • Tobacco user
  • Heavy alcohol user
  • Pregnancy (assessed by pregnancy test)
  • Lactation
  • Medications affecting iron bioavailability
  • Vitamin or mineral supplementation (other than vitamin B12)

Sites / Locations

  • Physical Activity and Nutrition Research Consortium

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

350 mg phytic acid

Arm Description

350 mg phytic acid (inositol hexaphosphate) at week 0 (before supplementation) and at week 4 (after supplementation)

Outcomes

Primary Outcome Measures

Change in baseline to endline area under the curve after meal challenge at weeks 0 and 4 of intervention
Change in area under the curve will be measured after administration of test meal including ferrous sulfate and condensed tannin supplementation at weeks 0 and 4
Change in baseline to endline hemoglobin and serum ferritin at weeks 0 and 4 of intervention
Change in ferritin and hemoglobin will be measured before administration of test meals at weeks 0 and 4
Change in salivary proteins at weeks 0 and 4 of intervention
HPLC determination of salivary proteins will be analyzed from saliva collected before and after test meals at weeks 0 and 4 of the intervention

Secondary Outcome Measures

Full Information

First Posted
January 23, 2017
Last Updated
January 24, 2017
Sponsor
Kansas State University
Collaborators
United States Department of Agriculture Foreign Agricultural Service, American Academy of Nurse Practitioners
search

1. Study Identification

Unique Protocol Identification Number
NCT03030703
Brief Title
Cystatin SN Binds to Phytic Acid and Predicts Non-heme Iron Bioavailability
Official Title
Salivary Cystatin SN Binds to Phytic Acid and is a Predictor of Non-heme Iron Bioavailability With Phytic Acid Supplementation
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
November 11, 2016 (Actual)
Primary Completion Date
December 10, 2016 (Actual)
Study Completion Date
December 10, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Kansas State University
Collaborators
United States Department of Agriculture Foreign Agricultural Service, American Academy of Nurse Practitioners

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Phytic acid is a known inhibitor of iron bioavailability, although long term studies have suggested possibly exaggerated findings compared to single meal studies, pointing to phytic acid adaptation over time. Salivary proline-rich proteins have been found to reduce tannin-iron chelation, but studies have not explored changes in salivary proteins that may result in phytic acid adaptation. The primary objectives of this study are: 1) To determine whether phytic acid impacts iron bioavailability or status when consumed over time 2) to test whether salivary protein production may impact iron bioavailability with phytic acid supplementation, and 3) to explore in vitro phytic acid salivary binding. Secondary objectives included assessment of the reliability of astringency as a measure of salivary protein production and iron absorption. The study was conducted in an iron absorption study of 7 women, aged 18-35 years old, to determine iron bioavailability with supplementation of 350 mg phytic acid before and after regular, three times daily supplementation for four weeks. Direct iron absorption was measured using area under the curve. Iron status was measured by changes in hemoglobin and ferritin, and was adjusted by participant c-reactive protein levels. Salivary samples were collected before and after supplement consumption during meal challenges, and analyzed on HPLC and by ELISA. Astringency testing was conducted at the end of each meal challenge. In vitro saliva-phytic acid modeling was explored on HPLC, MALDI-TOF, and ELISA. Iron absorption and status markers were analyzed by ANOVA, and mixed-modeling followed by pairwise comparison by least significant differences. Pearson's correlations were used to correlated salivary proteins and astringency with iron bioavailability. The present study will provide important information regarding the approximate influence of phytic acid consumption on iron bioavailability and storage over time in regards to salivary proteins. It will also give context to the role of salivary proteins with phytic acid consumption over time. Data will also help to delineate possible physiological mechanisms underlying phytic acid adaptation and possible ways to detect individuals who better adapt than others.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Iron-deficiency, Iron Deficiency Anemia
Keywords
Phytic acid, Cystatin, Salivary proline-rich protein, antinutrient

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
350 mg phytic acid
Arm Type
Experimental
Arm Description
350 mg phytic acid (inositol hexaphosphate) at week 0 (before supplementation) and at week 4 (after supplementation)
Intervention Type
Dietary Supplement
Intervention Name(s)
phytic acid
Other Intervention Name(s)
inositol hexaphosphate
Intervention Description
350 mg phytic acid (inositol hexaphosphate) three times daily for four weeks
Primary Outcome Measure Information:
Title
Change in baseline to endline area under the curve after meal challenge at weeks 0 and 4 of intervention
Description
Change in area under the curve will be measured after administration of test meal including ferrous sulfate and condensed tannin supplementation at weeks 0 and 4
Time Frame
Baseline and 4 weeks
Title
Change in baseline to endline hemoglobin and serum ferritin at weeks 0 and 4 of intervention
Description
Change in ferritin and hemoglobin will be measured before administration of test meals at weeks 0 and 4
Time Frame
Baseline and 4 weeks
Title
Change in salivary proteins at weeks 0 and 4 of intervention
Description
HPLC determination of salivary proteins will be analyzed from saliva collected before and after test meals at weeks 0 and 4 of the intervention
Time Frame
Baseline and 4 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Female, 18-35 years' old Non-obese BMI (18-29.9) Signed informed consent Exclusion Criteria: Oral disease Gastrointestinal disease Tobacco user Heavy alcohol user Pregnancy (assessed by pregnancy test) Lactation Medications affecting iron bioavailability Vitamin or mineral supplementation (other than vitamin B12)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Brian L Lindshield, Ph.D.
Organizational Affiliation
Kansas State University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Physical Activity and Nutrition Research Consortium
City
Manhattan
State/Province
Kansas
ZIP/Postal Code
66502
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Cystatin SN Binds to Phytic Acid and Predicts Non-heme Iron Bioavailability

We'll reach out to this number within 24 hrs